Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

ZS Pharma (Forth Worth, TX), a clinical-stage pharmaceutical company focused on the development of therapies to treat kidney and liver disease, closed a $46M Series C. Participants include Alta Partners, RiverVest Venture Partners, 3×5 Special Opportunity Partners, Salem Partners and Devon Park Bioventures. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and […]

Phosphate Therapeutics (London, United Kingdom) a clinical-stage biopharmaceutical company focused on small molecules phosphate binders for hyperphosphatemia and renal failure, closed a $13.8M Series A financing. Participants include Inventages Venture Capital.

CytoPherx (Ann Arbor, MI) a clinical-stage medical device company focused on dialysis filters to sequester and deactivate leukocytes in the patient’s blood system for acute renal failure, closed a $34M Series C financing. Participants include Early Stage Partners, Onset Ventures and Capital Midwest Fund.

CytoPherx (Ann Arbor, MI) a clinical-stage medical device company focused on dialysis filters to sequester and deactivate leukocytes in the patient’s blood system for acute renal failure, closed a $34M Series C financing. Participants include Early Stage Partners, Onset Ventures and Capital Midwest Fund.

Pharmalink (Sweden) a clinical-stage specialty pharmaceutical company focused on IgA nephritis, and conditioning prior to hematopoietic stem cell transplantation, closed a $5.3M Series C financing. Participants include Industrifonden.

Allena Pharmaceuticals (Newton, MA) a preclinical-stage biopharmaceutical company focused on nephrologic and urologic conditions, closed a $15M Series A financing. Participants include Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures.

Sorbent Therapeutics (Sunnyvale, CA) a clinical-stage biopharmaceutical company focused on development of adaptable non-absorbed polymeric drugs to for congestive heart failure, chronic kidney disease, end stage renal disease and hypertension, closed a $36M Series B financing. Participants include Novartis Venture Funds, Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem. Thanx for your patience as […]

AM-Pharma (The Netherlands) a clinical-stage pharmaceutical company focused on acute kidney injury and ulcerative colitis, closed a $39.8M Series D financing. Participants include Ysios Capital Partners, Kurma Life Science Partners, Abbott Ventures, Shire Ventures, BB Biotech Ventures, Idinvest Partners, Forbion Capital Partners and Inventages Venture Capital.

Sorbent Therapeutics (Sunnyvale, CA) a clinical-stage biopharmaceutical company focused on cardiovascular and renal disorders, closed a $36M Series B financing, bringing the total round to $53M. Participants include Novartis Venture Funds, Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem.

InVasc Therapeutics (Tucker, GA) a clinical-stage biopharmaceutical company focused on the cardiometabloic diseases chronic kidney disease and atherosclerosis, closed a $3.1M Series A financing. Participants include Trois I Investments Industriels Internationaux.

Sorbent Therapeutics (Sunnyvale, CA) a clinical-stage biopharmaceutical company focused on end stage renal disease, congestive heart failure, chronic kidney disease, and hypertension, closed a $21M Series B financing. Participants include AgeChem, CMEA Capital, ARCH Venture Partners, Sofinnova Ventures and Dow Venture Capital.

Reata Pharmaceuticals (Irving, TX) a clinical-stage small molecule company focused on inflammation modulation in chronic kidney disease, closed a $78M Series D financing. Participants include CPMG and Novo Ventures.

Action Pharma (Denmark) a clinical-stage biopharmaceutical company focused on acute kidney injury in patients undergoing cardiac surgery and inflammation, closed a $6.3M Series C financing. Participants include Sunstone Capital, Global Life Science Ventures, SLS Invest and InnovationsKapital.

« Previous Entries  Next Page »

to top of page...